A pilot study of virtual reality for inpatients with opioid use disorder.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9208821 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0391 (Electronic) Linking ISSN: 10550496 NLM ISO Abbreviation: Am J Addict Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Wiley-Blackwell
      Original Publication: Washington, DC : American Psychiatric Press, c1992-
    • Subject Terms:
      Opioid-Related Disorders*/therapy ; Opioid-Related Disorders*/psychology ; Virtual Reality* ; Inpatients*/psychology; Humans ; Pilot Projects ; Male ; Female ; Adult ; Substance Withdrawal Syndrome/psychology ; Feasibility Studies ; Middle Aged ; Craving ; Patient Satisfaction ; Virtual Reality Exposure Therapy/methods
    • Abstract:
      Background and Objectives: While inpatient withdrawal management/acute stabilization can improve outcomes for individuals with opioid use disorder (OUD), patients often leave treatment early due to mood, tension, and cravings associated with opioid withdrawal. The aim of this study was to evaluate the feasibility and preliminary effectiveness of a novel virtual reality (VR) based intervention; 3D Therapy Thrive (3DTT).
      Methods: Subjects with OUD (N = 32) were recruited from a community acute stabilization program and received up to two sessions of 3DTT. They completed questionnaires related to their overall satisfaction with the experience and side effects; as well as those related to mood, tension, and cravings.
      Results: There were no reported side effects and the majority of subjects (94%) reported high satisfaction with the experience. Out of 62 patients approached, 33 patients agreed to participate (53%) 33 patients completed one, and 17 of these patients (52%) completed both sessions of 3DTT, with 19 participants (58%) completing their treatment protocols. Compared to baseline, 3DTT participants reported significant reductions in depression, tension, and cravings (p's < 0.001).
      Discussion and Conclusions: This pilot study supports the feasibility and preliminary effectiveness of 3DTT for improving outcomes for inpatients with OUD. Future randomized controlled trials are necessary to evaluate the efficacy of 3DTT for improving retention, reducing cravings, and improving mood and tension.
      Scientific Significance: This is the first study to evaluate the feasibility of a psychologically informed VR intervention in inpatients with OUD.
      (© 2024 The American Academy of Addiction Psychiatry (AAAP).)
    • References:
      Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health; 2021. https://www.samhsa.gov/data/.
      Friedman JR, Hansen H. Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID‐19 pandemic. JAMA Psychiatry. 2022;79(4):379‐381. doi:10.1001/jamapsychiatry.2022.0004.
      Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350. doi:10.1016/j.drugalcdep.2020.108350.
      Jones CM, McCance‐Katz EF. Co‐occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78‐82. doi:10.1016/j.drugalcdep.2018.12.030.
      Walley AY, Lodi S, Li Y, et al. Association between mortality rates and medication and residential treatment after in‐patient medically managed opioid withdrawal: a cohort analysis. Addiction. 2020;115(8):1496‐1508. doi:10.1111/add.14964.
      Gold AK, Stathopoulou G, Otto MW. Emotion regulation and motives for illicit drug use in opioid‐dependent patients. Cogn Behav Ther. 2020;49(1):74‐80. doi:10.1080/16506073.2019.1579256.
      Cheetham A, Allen NB, Yücel M, Lubman DI. The role of affective dysregulation in drug addiction. Clin Psychol Rev. 2010;30(6):621‐634. doi:10.1016/j.cpr.2010.04.005.
      Simon R, Snow R, Wakeman S. Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study. Subst Abus. 2020;41(4):519‐525. doi:10.1080/08897077.2019.1671942.
      Hudak J, Prince KC, Marchand WR, et al. The temporal dynamics of emotion dysregulation in prescription opioid misuse. Prog Neuropsychopharmacol Biol Psychiatry. 2021;104:110024. doi:10.1016/j.pnpbp.2020.110024.
      Pergolizzi Jr. JV, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther. 2020;45(5):892‐903. doi:10.1111/jcpt.13114.
      McHugh RK, Weiss RD, Cornelius M, Martel MO, Jamison RN, Edwards RR. Distress intolerance and prescription opioid misuse among patients with chronic pain. J Pain. 2016;17(7):806‐814. doi:10.1016/j.jpain.2016.03.004.
      Li J, Weidacker K, Mandali A, et al. Impulsivity and craving in subjects with opioid use disorder on methadone maintenance treatment. Drug Alcohol Depend. 2021;219:108483. doi:10.1016/j.drugalcdep.2020.108483.
      Provost SE, Griffin ML, Hilton BT, et al. Correlates of optimism among patients in substance use disorder inpatient treatment. Am J Addict. 2022;31(6):494‐501. doi:10.1111/ajad.13324.
      Taubin D, Berger A, Greenwald D, et al. A systematic review of virtual reality therapies for substance use disorders: impact on secondary treatment outcomes. Am J Addict. 2022;32(1):13‐23.
      Segawa T, Baudry T, Bourla A, et al. Virtual reality (VR) in assessment and treatment of addictive disorders: a systematic review. Front Neurosci. 2020;13:13. doi:10.3389/fnins.2019.01409.
      Jiang MYW, Upton E, Newby JM. A randomised wait‐list controlled pilot trial of one‐session virtual reality exposure therapy for blood‐injection‐injury phobias. J Affect Disord. 2020;276:636‐645. doi:10.1016/j.jad.2020.07.076.
      Darnall BD, Krishnamurthy P, Tsuei J, Minor JD. Self‐administered skills‐based virtual reality intervention for chronic pain: randomized controlled pilot study. JMIR Form Res. 2020;4(7):e17293. doi:10.2196/17293.
      Garcia LM, Birckhead BJ, Krishnamurthy P, et al. An 8‐week self‐administered at‐home behavioral skills‐based virtual reality program for chronic low back pain: double‐blind, randomized, placebo‐controlled trial conducted during COVID‐19. J Med Internet Res. 2021;23(2):e26292. doi:10.2196/26292.
      Greenwald HJ. The Psychological Brain: A New Paradigm for Understanding How the Mind Works. Essential Concepts Press; 2018.
      Seabrook E, Kelly R, Foley F, et al. Understanding how virtual reality can support mindfulness practice: mixed methods study. J Med Internet Res. 2020;22(3):e16106. doi:10.2196/16106.
      Arpaia P, D'Errico G, De Paolis LT, Moccaldi N, Nuccetelli F. A narrative review of mindfulness‐based interventions using virtual reality. Mindfulness. 2022;13(3):556‐571. doi:10.1007/s12671-021-01783-6.
      Maricich YA, Xiong X, Gerwien R, et al. Real‐world evidence for a prescription digital therapeutic to treat opioid use disorder. Curr Med Res Opin. 2021;37(2):175‐183. doi:10.1080/03007995.2020.1846023.
      Piotrowski C. Virtual reality research: a bibliometric analysis of the contemporary mental health literature. North Am J Psychol. 2022;24(3):369‐380.
      Wang Y, Liu M, Shen Z. A virtual reality counterconditioning procedure to reduce methamphetamine cue‐induced craving. J Psychiatr Res. 2019;116:88‐94. doi:10.1016/j.jpsychires.2019.06.007.
      Gamito P, Oliveira J, Matias M, et al. Virtual reality cognitive training among individuals with alcohol use disorder undergoing residential treatment: pilot randomized controlled trial. J Med Internet Res. 2021;23(1):e18482. doi:10.2196/18482.
      Faraj MM, Lipanski NM, Morales A, et al. A virtual reality meditative intervention modulates pain and the pain neuromatrix in patients with opioid use disorder. Pain Med. 2021;22:2739‐2753. doi:10.1093/pm/pnab162.
      Marissen MAE, Franken IHA, Blanken P, van den Brink W, Hendriks VM. Cue exposure therapy for the treatment of opiate addiction: results of a randomized controlled clinical trial. Psychother Psychosom. 2007;76(2):97‐105. doi:10.1159/000097968.
      Greenwald H, Greenwald D, Johnson‐Smith P, et al. Uncovering psychological factors in opioid use disorder. Presented at: AAAP Annual Conference; December 8, 2022; Naples, FL.
      Sipe WEB, Eisendrath SJ. Mindfulness‐based cognitive therapy: theory and practice. Can J Psychiatry. 2012;57(2):63‐69.
      Meta. Oculus VR Quest 2 manual. Accessed March 17, 2023. https://www.manua.ls/oculus-vr/quest-2/manual.
      Gil‐Gómez J, Gil‐Gómez H, Lozano‐Quilis J, Manzano‐Hernández P, Albiol‐Pérez S, Aula‐Valero C. SEQ: Suitability Evaluation Questionnaire for Virtual Rehabilitation systems. Application in a Virtual Rehabilitation system for Balance Rehabilitation. IEEE; 2013:335‐338.
      Grove JR, Prapavessis H. Preliminary evidence for the reliability and validity of an abbreviated profile of mood states. Int J Sport Psychol. 1992;23(2):93‐109.
      Pang RD, Chai SH, Tucker CJ, Weinberger AH, D'Orazio LM, Kirkpatrick MG. Effects of cigarette abstinence on negative and positive affect by depression symptom levels: a lab study. J Affect Disord. 2022;307:163‐170. doi:10.1016/j.jad.2022.03.052.
      Spinella M. Compulsive behavior in tobacco users. Addict Behav. 2005;30(1):183‐186. doi:10.1016/j.addbeh.2004.04.011.
      McMillan DE, Gilmore‐Thomas K. Stability of opioid craving over time as measured by visual analog scales. Drug Alcohol Depend. 1996;40(3):235‐239. doi:10.1016/0376-8716(96)01218-5.
      Hogan LM, Jabeen Q, Race J, Rettie H. Inpatient detoxification: examining factors leading to early discharge. Alcohol Treat Q. 2018;36(3):366‐372. doi:10.1080/07347324.2018.1424591.
      Tenny S, Hoffman MR. Odds ratio. StatPearls. StatPearls Publishing LLC; 2023.
      Fleischmann M, Vaughan B. Commentary: statistical significance and clinical significance—a call to consider patient reported outcome measures, effect size, confidence interval and minimal clinically important difference (MCID). J Bodyw Mov Ther. 2019;23(4):690‐694. doi:10.1016/j.jbmt.2019.02.009.
      Sullivan GM, Feinn R. Using effect size‐or why the P value is not enough. J Grad Med Educ. 2012;4(3):279‐282. doi:10.4300/jgme-d-12-00156.1.
      Caserman P, Garcia‐Agundez A, Gámez Zerban A, Göbel S. Cybersickness in current‐generation virtual reality head‐mounted displays: systematic review and outlook. Virtual Reality. 2021;25(4):1153‐1170.
      Chattha UA, Janjua UI, Anwar F, Madni TM, Cheema MF, Janjua SI. Motion sickness in virtual reality: an empirical evaluation. IEEE Access. 2020;8:130486‐130499. doi:10.1109/ACCESS.2020.3007076.
      Munafo J, Diedrick M, Stoffregen TA. The virtual reality head‐mounted display Oculus Rift induces motion sickness and is sexist in its effects. Exp Brain Res. 2017;235(3):889‐901. doi:10.1007/s00221-016-4846-7.
    • Grant Information:
      Mass General Brigham; 3D Therapy LLC
    • Publication Date:
      Date Created: 20240302 Date Completed: 20240626 Latest Revision: 20240722
    • Publication Date:
      20240722
    • Accession Number:
      10.1111/ajad.13526
    • Accession Number:
      38430207